摘要
目的 分析孟鲁司特钠联合氨溴索治疗重症肺炎的疗效和对患者肺功能,血气指标和炎症因子的影响。方法 选取2020年8月至2022年2月在本院治疗的支原体肺炎患者100例作为本次研究对象,其中50例患者接受盐酸氨溴索治疗纳入本次对照组,另外50例患者接受盐酸氨溴索添加孟鲁司特钠治疗纳入研究组。比较两组患者临床疗效,气促缓解时间、心率恢复时间、住院时间缓解情况。比较两组患者用力肺活量(FVC)和第1秒用力呼气容积(FEV1),计算FEV1/FVC。比较两组患者动脉血二氧化碳分压(PaCO_(2))、动脉血氧分压(PaO_(2)),血氧饱和度(SaO_(2))、肿瘤坏死因子(TNF)-α、超敏C反应蛋白(hs-CRP)、白细胞介素-6 (IL-6)。结果结果 研究组显效患者为有效治疗率显著高于对照组患者(P<0.05)。研究组患者气促缓解时间、心率恢复时间、住院时间均短于对照组(P<0.05)。研究组患者治疗后FVC,FEV1,FEV1/FVC,PaO2及SaO2均升高且高于对照组(P<0.05),而PaCO_(2)降低且低于对照组(P<0.05)。研究组患者治疗后TNF-α、hs-CRP、IL-6水平显著低于对照组(P<0.05)。结论 孟鲁司特钠联合氨溴索可以显著提高重症肺炎患者的临床疗效,改善肺功能,降低血清中的炎性因子水平。
Objective To evaluate the effectiveness of combined montelukast sodium and ambroxol treatment in severe pneumonia and its impact on lung function,blood gases,and inflammatory markers.MethodsThis study involved 100 Mycoplasma pneumonia patients treated at our hospital from August 2020 to February 2022.Fifty patients received ambroxol hydrochloride and were classified as the control group,while the remaining fifty,treated with both ambroxol hydrochloride and montelukast sodium,formed the study group.We compared clinical outcomes,dyspnea resolution time,heart rate normalization,and length of hospital stay between the groups.Pulmonary function tests included Forced Vital Capacity(FVC)and Forced Expiratory Volume in one second(FEV1),from which FEV1/FVC ratios were derived.Additionally,we assessed arterial blood gases—carbon dioxide partial pressure(PaCO_(2))and oxygen partial pressure(PaO2)—along with oxygen saturation(SaO_(2)),tumor necrosis factor-alpha(TNF-α),high-sensitivity C-reactive protein(hs-CRP),and interleukin-6(IL-6)levels.ResultsThe study group exhibited a significantly higher effective treatment rate(P<0.05).They also showed shorter durations of dyspnea relief,heart rate recovery,and hospital stays(P<0.05).Post-treatment assessments revealed increased FVC,FEV1,FEV1/FVC,PaO_(2),and SaO_(2),and decreased PaCO_(2) in the study group compared to controls(P<0.05).Furthermore,TNF-α,hs-CRP,and IL-6 were significantly reduced in the study group post-treatment(P<0.05).ConclusionThe combination of montelukast sodium with ambroxol markedly enhances clinical outcomes in severe pneumonia patients,improves pulmonary function,and reduces serum levels of inflammatory markers.
作者
韦雪丽
汪艳娟
米聪
WEI Xue-li;WANG Yan-juan;MI Cong(Shangqiu First People's Hospital,Shangqiu 476000,Henan Province,China)
出处
《罕少疾病杂志》
2024年第6期44-46,共3页
Journal of Rare and Uncommon Diseases
基金
河南省医学科技攻关计划(联合共建)项目(LHGJ20190911)。
关键词
孟鲁司特钠
氨溴索
重症肺炎
临床效果
Montelukast Sodium
Ambroxol
Severe Pneumonia
Clinical Effect
